Table 6.
Meta-analysis of association between clinicopathological parameters and HER3, Akt, p-Akt, mTOR, p-mTOR expression in gastric cancer
| Target proteins | Parameters | Number of studies | Number of patients | Heterogeneity | Model | OR(95%CI) | P value | |
|---|---|---|---|---|---|---|---|---|
| I 2 (%) | P value | |||||||
| HER3 | Sex (male/female) | 5 | 1034 | 18 | 0.30 | FE | 0.89(0.66,1.20) | 0.44 |
| Depth of invasion (T3 + T4/T1 + T2) | 4 | 900 | 34 | 0.20 | FE | 2.39(1.62,3.54) | <0.001 | |
| LN metastasis(positive/negative) | 5 | 1034 | 68 | 0.02 | RE | 2.35(1.34,4.11) | 0.003 | |
| Metastasis (positive/negative) | 5 | 1034 | 47 | 0.10 | FE | 1.39(0.66,2.91) | 0.39 | |
| Tumor stage (III + IV/I + II) | 4 | 801 | 54 | 0.09 | RE | 1.38(0.76,2.49) | 0.29 | |
| Akt | Sex (male/female) | 3 | 501 | 0 | 0.67 | FE | 0.99(0.66,1.49) | 0.96 |
| Age (>60/<60) | 2 | 190 | 89 | 0 | RE | 1.24(0.17,8.88) | 0.83 | |
| Tumor location (upper/low) | 2 | 431 | 71 | 0.05 | RE | 0.69(0.26,1.79) | 0.44 | |
| Differentiation (poor/well) | 2 | 190 | 77 | 0.04 | RE | 1.63(0.35,7.53) | 0.53 | |
| Depth of invasion (T3 + T4/T1 + T2) | 1 | 120 | – | – | – | 1.18(0.45,3.10) | 0.74 | |
| LN metastasis(positive/negative) | 3 | 501 | 68 | 0.05 | RE | 1.27(0.44,3.61) | 0.66 | |
| Metastasis (positive/negative) | 3 | 501 | 72 | 0.03 | RE | 1.04(0.24,4.46) | 0.96 | |
| Tumor stage (III + IV/I + II) | 3 | 501 | 70 | 0.04 | RE | 1.17(0.45,3.00) | 0.75 | |
| p-Akt | Sex (male/female) | 9 | 1477 | 0 | 0.79 | FE | 1.29(1.03,1.63) | 0.03 |
| Age (>60/<60) | 5 | 1326 | 0 | 0.79 | FE | 0.95(0.74,1.20) | 0.65 | |
| Tumor location (upper/low) | 4 | 895 | 0 | 0.70 | FE | 1.03(0.78,1.37) | 0.81 | |
| Differentiation (poor/well) | 7 | 996 | 65 | 0.01 | RE | 1.14(0.65,2.02) | 0.64 | |
| Depth of invasion (T3 + T4/T1 + T2) | 7 | 1283 | 60 | 0.02 | RE | 1.23(0.80,1.90) | 0.35 | |
| LN metastasis(positive/negative) | 12 | 2019 | 69 | 0.00 | RE | 1.29(0.88,1.89) | 0.19 | |
| Metastasis (positive/negative) | 5 | 1351 | 66 | 0.02 | RE | 0.75(0.29,1.89) | 0.54 | |
| Tumor stage (III + IV/I + II) | 11 | 1597 | 62 | 0.003 | RE | 1.20(0.81,1.79) | 0.36 | |
| mTOR | Sex (male/female) | 4 | 1637 | 0 | 0.95 | FE | 1.16(0.94,1.43) | 0.17 |
| Age (>60/<60) | 2 | 1192 | 88 | 0.004 | RE | 1.90(0.59,6.06) | 0.28 | |
| Tumor location (upper/low) | 2 | 1148 | 0 | 0.87 | FE | 1.30(1.03,1.64) | 0.03 | |
| Differentiation (poor/well) | 3 | 1225 | 88 | 0 | RE | 1.59(0.33,7.57) | 0.56 | |
| Depth of invasion (T3 + T4/T1 + T2) | 3 | 1604 | 57 | 0.10 | RE | 0.88(0.59,1.31) | 0.54 | |
| LN metastasis(positive/negative) | 4 | 1637 | 74 | 0.01 | RE | 1.72(0.98,3.01) | 0.06 | |
| Tumor stage (III + IV/I + II) | 3 | 1225 | 89 | 0 | RE | 3.13(0.72,13.61) | 0.13 | |
| p-mTOR | Sex (male/female) | 8 | 2994 | 0 | 0.60 | FE | 1.09(0.93,1.28) | 0.30 |
| Age (>60/<60) | 5 | 2469 | 0 | 0.44 | FE | 1.46(1.24,1.72) | <0.001 | |
| Tumor location (upper/low) | 5 | 2001 | 11 | 0.35 | FE | 1.26(1.03,1.55) | 0.03 | |
| Differentiation (poor/well) | 4 | 1663 | 75 | 0.01 | RE | 0.99(0.57,1.72) | 0.87 | |
| Depth of invasion (T3 + T4/T1 + T2) | 4 | 1751 | 54 | 0.06 | RE | 1.63(1.08,2.45) | 0.02 | |
| LN metastasis(positive/negative) | 7 | 2294 | 90 | 0 | RE | 1.57(0.83,2.98) | 0.17 | |
| Metastasis (positive/negative) | 2 | 246 | 58 | 0.12 | RE | 1.05(0.25,4.44) | 0.94 | |
| Tumor stage (III + IV/I + II) | 6 | 2595 | 58 | 0.04 | RE | 1.73(1.29,2.32) | <0.001 | |
OR odds ratio, CI confidence interval, FE fixed-effect model, RE random-effect model, LN metastasis: lymph node metastasis